Latest Biotech News

GSK and Spero Therapeutics reported Phase 3 non‑inferiority results for tebipenem HBr versus the standard of care, validating the oral antibiotic’s potential to match IV therapy and prompting...

10x Genomics filed patent litigation against Illumina in Delaware federal court, alleging infringement tied to single‑cell and spatial transcriptomics technologies as the two firms intensify...

Galapagos announced it could not find a buyer for its cell therapy unit and will wind down the business, a decision that will lead to the closure of facilities in Europe, China and the U.S. and...

Sanofi struck a collaboration and licensing deal with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales targets, giving...

Hologic agreed to be acquired by funds led by Blackstone and TPG in a transaction valued up to $18.3 billion, including contingent value rights tied to breast-health revenue targets. The board...

Replimune announced that the FDA accepted a resubmitted biologics license application for RP1, an oncolytic HSV‑based therapy given with PD‑1 blockade, setting a new decision date in April 2026....

Exelixis plans an NDA submission for zanzalintinib after detailed Stellar‑303 Phase III results showed an overall survival benefit when the oral TKI was combined with atezolizumab versus...

An international, multicenter study reported at ESMO and in associated publications that circulating tumor DNA (ctDNA) testing can stratify recurrence risk after surgery for muscle‑invasive...

Cancer‑screening firm Grail announced a $325 million private placement to fund commercial expansion, reimbursement push and working capital for its multi‑cancer detection Galleri blood test. The...

10x Genomics filed two patent infringement suits against Illumina in Delaware federal court, alleging the sequencing giant infringed intellectual property tied to single‑cell and spatial...

Danaher’s Integrated DNA Technologies (IDT) announced a collaboration with Profluent Bio to use Profluent’s ProGen3 foundation model for AI‑driven enzyme design, combining IDT’s enzymology and...

A Nature Biotechnology paper introduced an epigenetic editing platform enabling safe, multiplexed gene programming in primary human T cells to enhance CAR‑T potency and manufacturability. The...

Step Pharma closed a €38 million Series C to advance its CTPS1 inhibitor dencatistat across multiple hematologic and solid tumor studies, financing trials across lymphomas and solid tumors and...

Sanofi signed a collaboration and licensing agreement with Evoq Therapeutics that could deliver more than $500 million in milestone payments tied to preclinical, development and sales goals. Evoq...

10x Genomics filed patent infringement lawsuits against Illumina in Delaware federal court, accusing the sequencing giant of using its patented single-cell and spatial genomics technologies to...

Grail raised approximately $325 million in a private placement to bolster commercial activities, reimbursement efforts and working capital as the company prepares regulatory filings and market...

The U.S. Food and Drug Administration accepted Replimune’s resubmitted biologics license application for RP1, an oncolytic herpesvirus engineered to prime immune responses, and set a target...

Galapagos announced plans to wind down its cell therapy program after an active divestment process failed to surface acceptable buyers. Non-binding offers were reportedly dominated by financial...

Exelixis reported detailed STELLAR‑303 data showing its oral TKI zanzalintinib plus atezolizumab reduced risk of death vs. regorafenib in previously treated metastatic colorectal cancer, and the...

Data presented at ESMO strengthened the case for circulating tumor DNA (ctDNA) to guide adjuvant treatment decisions. Roche reported a phase 3 analysis showing adjuvant atezolizumab provided a...